Published in Drug Week, February 11th, 2005
The agreement will provide Roche with access to NanoCrystal technology and the right to apply it to a number of proprietary drug candidates.
Elan will receive development milestones and royalties on sales of any product incorporating the use of NanoCrystal technology.
Paul Breen, executive vice president, global services & operations, Elan, said, "We are very pleased to broaden our license agreement with Roche. This agreement highlights the robustness of the technology and the interest of pharmaceutical companies to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.